Cargando…

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mollica, Veronica, Rizzo, Alessandro, Montironi, Rodolfo, Cheng, Liang, Giunchi, Francesca, Schiavina, Riccardo, Santoni, Matteo, Fiorentino, Michelangelo, Lopez-Beltran, Antonio, Brunocilla, Eugenio, Brandi, Giovanni, Massari, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352972/ https://www.ncbi.nlm.nih.gov/pubmed/32498352 http://dx.doi.org/10.3390/cancers12061449

Ejemplares similares

TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Is There a Role for Immunotherapy in Prostate Cancer?
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study
por: Franceschini, Tania, et al.
Publicado: (2021)

The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
por: Marchetti, Andrea, et al.
Publicado: (2021)

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Multiparametric magnetic resonance imaging for the differential diagnosis between granulomatous prostatitis and prostate cancer: a literature review to an intriguing diagnostic challenge
por: Gaudiano, Caterina, et al.
Publicado: (2023)

PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022)

Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
por: Mollica, Veronica, et al.
Publicado: (2021)

Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
por: Mollica, Veronica, et al.
Publicado: (2021)

Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
por: Aurilio, Gaetano, et al.
Publicado: (2021)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis
por: Giunchi, Francesca, et al.
Publicado: (2020)

Beyond Multiparametric MRI and towards Radiomics to Detect Prostate Cancer: A Machine Learning Model to Predict Clinically Significant Lesions
por: Gaudiano, Caterina, et al.
Publicado: (2022)

The Human Microbiota and Prostate Cancer: Friend or Foe?
por: Massari, Francesco, et al.
Publicado: (2019)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Towards a new WHO classification of renal cell tumor: what the clinician needs to know—a narrative review
por: Cimadamore, Alessia, et al.
Publicado: (2021)

Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Genomics and Immunomics in the Treatment of Urothelial Carcinoma
por: Mollica, Veronica, et al.
Publicado: (2022)

Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
por: Mollica, Veronica, et al.
Publicado: (2019)

The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

An Apparent Diffusion Coefficient-Based Machine Learning Model Can Improve Prostate Cancer Detection in the Grey Area of the Prostate Imaging Reporting and Data System Category 3: A Single-Centre Experience
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough
por: Mollica, Veronica, et al.
Publicado: (2021)

The Role of [(18)F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET/CT and Histopathological Analysis
por: Zanoni, Lucia, et al.
Publicado: (2021)

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach
por: Fiorentino, Michelangelo, et al.
Publicado: (2016)

Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers
por: Santoni, Matteo, et al.
Publicado: (2019)

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
por: Mollica, Veronica, et al.
Publicado: (2019)

Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT
por: Ricci, Costantino, et al.
Publicado: (2023)

Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter
por: Bianconi, Maristella, et al.
Publicado: (2019)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with (68)Ga-PSMA PET/CT Features in Primary Staging
por: Vetrone, Luigia, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
por: Modena, Alessandra, et al.
Publicado: (2016)

Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer
por: Maloberti, Thais, et al.
Publicado: (2023)

A case report of myoid gonadal stromal tumor treated with testis sparing surgery
por: Ercolino, Amelio, et al.
Publicado: (2022)

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer
por: Mollica, Veronica, et al.
Publicado: (2020)

Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy
por: Cimadamore, Alessia, et al.
Publicado: (2019)

Microbiome and Cancers, With Focus on Genitourinary Tumors
por: Cimadamore, Alessia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0dfk075lfcrb3h5f69h67at022